| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:Mps1-IN-5
CAS:2890819-31-3
Package:1removed
|
Mps1-IN-5 manufacturers
- Mps1-IN-5
-
- $2500.00
-
2026-05-11
- CAS:2890819-31-3
- Purity:
- Supply Ability: 10g
|
| | Mps1-IN-5 Basic information |
| Product Name: | Mps1-IN-5 | | Synonyms: | 1H-Pyrazolo[3,4-d]pyrimidin-6-amine, 1-(3-amino-1-methyl-1H-indazol-5-yl)-N-[4-(4-methyl-1-piperazinyl)phenyl]- | | CAS: | 2890819-31-3 | | MF: | C24H26N10 | | MW: | 454.53 | | EINECS: | | | Product Categories: | | | Mol File: | 2890819-31-3.mol |  |
| | Mps1-IN-5 Chemical Properties |
| Boiling point | 691.211±65.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.470±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 7.889±0.42(predicted) |
| | Mps1-IN-5 Usage And Synthesis |
| Uses | Mps1-IN-5 is a potent and orally active Mps1 inhibitor with an IC50 value of 29 nM. Mps1-IN-5 induces Apoptosis and cell cycle arrests at G2/M phase. Mps1-IN-5 shows antiproliferative activity and anti-tumor activity. Mps1-IN-5 inhibits phosphorylation of Mps1 and induces DNA damage[1]. | | in vivo | Mps1-IN-5 (30, 60 mg/kg; p.o.; daily for 15 days) inhibits tumor growth without obvious toxicity in breast cancer models[1]. | Animal Model: | 6-8 weeks, female BALB/C mice (4T1-luc mouse xenograft model)[1] | | Dosage: | 30, 60 mg/kg | | Administration: | P.o.; daily for 15 days | | Result: | Significantly suppressed tumor growth and caused negligible damage to organs such as heart, liver, spleen, lung and kidneys. |
| | References | [1] Li X, et al. Design, synthesis and biological evaluation of a new class of 7H-pyrrolo[2,3-d]pyrimidine derivatives as Mps1 inhibitors for the treatment of breast cancer. Eur J Med Chem. 2023 Jan 5;245(Pt 1):114887. |
| | Mps1-IN-5 Preparation Products And Raw materials |
|